ICU Medical (ICUI) Earnings Analysis
ICU Medical (ICUI) next reports earnings on 2026-08-06, consensus EPS 1.91 USD. Last quarter (2026-05-07) it beat with EPS 1.97 USD vs 1.78 USD est (+10.7%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E 84.19.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ICUI next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 1.91 USD |
| Revenue estimate | 0.53B |
ICUI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 1.97 USD | 1.78 USD | +10.7% | Beat |
| 2026-02-19 | 1.91 USD | 1.68 USD | +13.7% | Beat |
| 2025-11-06 | 2.03 USD | 1.43 USD | +42% | Beat |
| 2025-08-07 | 2.1 USD | 1.44 USD | +45.8% | Beat |
| 2025-05-08 | 1.72 USD | 1.23 USD | +39.8% | Beat |
| 2025-02-27 | 2.11 USD | 1.48 USD | +42.6% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
ICUI valuation and analyst view
| Trailing P/E | 84.19 |
|---|---|
| Trailing EPS | 1.871 USD |
| Price / book | 1.85 |
| Dividend yield | 0.00% |
| Market cap | 3.97B |
| Analyst consensus | Buy (10 buy / 1 hold / 0 sell) |
| Avg price target | 170.25 USD |
Related research pages
Frequently asked questions
When is ICU Medical (ICUI)'s next earnings date?
ICU Medical is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 1.91 USD and revenue estimate of 0.53B.
Did ICUI beat earnings last quarter?
In its 2026-05-07 report, ICUI posted EPS of 1.97 USD versus a 1.78 USD estimate — a beat of 10.7%.
What is ICUI's earnings track record?
Over the last 6 reported quarters with consensus data, ICUI beat estimates 6 times (100%).
What is ICUI's current P/E ratio and EPS?
ICUI trades at a trailing P/E of 84.19 on trailing EPS of 1.8712647391374575 USD.
What do analysts rate ICUI?
Analyst consensus is "Buy" across 11 ratings (1 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 170.25 USD.